Last reviewed · How we verify
Risk of low dose aspirin discontinuation
Risk of low dose aspirin discontinuation is a Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development.
At a glance
| Generic name | Risk of low dose aspirin discontinuation |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Aspirin 150 mg vs 100 mg for Prevention of Preeclampsia in High-Risk Obese Pregnant Women (PHASE3)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses (PHASE1)
- IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy (PHASE2)
- Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia (PHASE3)
- STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation (NA)
- Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risk of low dose aspirin discontinuation CI brief — competitive landscape report
- Risk of low dose aspirin discontinuation updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Risk of low dose aspirin discontinuation
What is Risk of low dose aspirin discontinuation?
Risk of low dose aspirin discontinuation is a Small molecule drug developed by AstraZeneca.
Who makes Risk of low dose aspirin discontinuation?
Risk of low dose aspirin discontinuation is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What development phase is Risk of low dose aspirin discontinuation in?
Risk of low dose aspirin discontinuation is in Phase 2.